Pacira BioSciences (PCRX) Total Liabilities (2010 - 2026)

Pacira BioSciences' Total Liabilities history runs 17 years deep, the most recent figure standing at $554.6 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 29.63% year-over-year to $554.6 million; the TTM figure through Mar 2026 stood at $554.6 million (down 29.63% YoY), while the FY2025 annual figure was $571.8 million, down 26.23% from the prior year.
• Total Liabilities was $554.6 million for Q1 2026 at Pacira BioSciences, down from $571.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $1.2 billion in Q1 2022 to a low of $554.6 million in Q1 2026.
• Historically, Total Liabilities has averaged $776.3 million across 5 years, with a median of $767.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities surged 85.62% in 2022, then tumbled 36.09% in 2023.
• A 5-year view of Total Liabilities shows it stood at $906.2 million in 2022, then fell by 22.28% to $704.3 million in 2023, then advanced by 10.07% to $775.2 million in 2024, then slipped by 26.23% to $571.8 million in 2025, then dropped by 3.0% to $554.6 million in 2026.
• The last three Total Liabilities figures came in at $554.6 million (Q1 2026), $571.8 million (Q4 2025), and $570.4 million (Q3 2025), per Business Quant data.